ahlam1399
03-02-2016, 05:35 AM
UK cost agency rejects leukaemia drug from J&J and AbbVie
LONDON, March 2 (Reuters) - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's healthcare cost-effectiveness agency NICE, which said it could **t be confident the medicine represented an effective use of resources.
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/1/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/1/rc.htm)
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/2/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/2/rc.htm)
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/3/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/3/rc.htm)
http://da.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2.img (http://da.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2.htm)
http://adchoice.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/ach.img (http://adchoice.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/ach.htm)http://pi.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2t.imghttp://pi2.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4df7415a/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=MPQxwT5hFaA:-HYLpsCPH4Y:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=MPQxwT5hFaA:-HYLpsCPH4Y:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/MPQxwT5hFaA
LONDON, March 2 (Reuters) - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's healthcare cost-effectiveness agency NICE, which said it could **t be confident the medicine represented an effective use of resources.
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/1/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/1/rc.htm)
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/2/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/2/rc.htm)
http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/3/rc.img (http://rc.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/rc/3/rc.htm)
http://da.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2.img (http://da.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2.htm)
http://adchoice.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/ach.img (http://adchoice.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/ach.htm)http://pi.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2t.imghttp://pi2.feedsportal.com/r/247393357090/u/49/f/654213/c/35217/s/4df7415a/sc/13/a2t2.imghttp://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4df7415a/sc/13/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=MPQxwT5hFaA:-HYLpsCPH4Y:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=MPQxwT5hFaA:-HYLpsCPH4Y:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=MPQxwT5hFaA:-HYLpsCPH4Y:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/MPQxwT5hFaA